Prevention of sex-specific olanzapine-induced hyperphagia and weight gain in Drosophila melanogaster by treatment with Elecampane (Inula helenium L.)

Rationale. Despite the high clinical efficacy of the atypical antipsychotic drug olanzapine, its use is limited by serious metabolic side effects, including hyperphagia, weight gain, obesity, dyslipidemia, and insulin resistance.

The aim. To study the effect of Inula helenium L. extract on the development of metabolic side effects induced by the atypical antipsychotic drug olanzapine using the Drosophila melanogaster model.

Materials and methods. Male and female Drosophila melanogaster were maintained on standard medium supplemented with olanzapine (1 pg/ml) and/or Inula helenium L. extract (50 pg/ml) for 7 days. Food seeking/preference behavior was determined using the geotaxis behavioral test. The body weight of individual flies was determined using an analytical balance.

Results. Olanzapine induced marked hyperphagia and weight gain, especially in males (~90 % increase in body weight). Addition of Inula helenium L. extract together with olanzapine completely prevented olanzapine-induced hyperphagia and weight gain in males; in females, the blocking effect was not observed. Administration of the extract alone had no effect on behavioral and morphometric parameters.

Conclusion. Inula helenium L. extract exhibits protective properties against the metabolic side effects of olanzapine in a gender-specific manner, making it a promising candidate for the development of adjuvant agents in antipsychotic therapy. The obtained results demonstrate for the first time in an invertebrate model the potential of phytoextracts to modulate the metabolic side effects of drugs.

1. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939-951. doi: 10.1016/S0140-6736(19)31135-3

2. Kang D, Lu J, Liu W, Shao P, Wu R. Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences. Schizophrenia (Heidelb). 2022; 8(1): 9. doi: 10.1038/s41537-022-00211-5

3. Li S, Zheng D, Wang W, Liu N, Li Y, Lu C, et al. Olanzapine-Induced Weight Gain and Glycolipid Metabolism Aberrations in First-Episode and Antipsychotic-Naive Schizophrenia Patients: A Longitudinal Study. Curr Neuropharmacol. 2025; 23(7): 771-779. doi: 10.2174/1570159X23666240918103730

4. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7(1): 64-77. doi: 10.1016/S2215-0366(19)30416-X

5. Huang J, Hei GR, Yang Y, Liu CC, Xiao JM, Long YJ, Peng XJ, et al. Increased Appetite Plays a Key Role in Olan-zapine-Induced Weight Gain in First-Episode Schizophrenia Patients. Front Pharmacol. 2020; 11: 739. doi: 10.3389/fphar.2020.00739

6. Sudar FP, Zekerallah SS, Paulzen M, Mathiak K, Gaebler AJ. Unraveling antipsychotic induced weight gain in schizophrenia - A proof-of-concept study exploring the impact of the cumulative historical occupancy of different receptors by antipsychotics. Psychiatry Res. 2025; 348: 116452. doi: 10.1016/j.psychres.2025.116452

7. Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation of Olanzapine-Induced Weight Gain with Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients with Schizophrenia. Am J Psychiatry. 2019; 176(6): 457-467. doi: 10.1176/appi.ajp.2018.18030280

8. Zheng X, Wu Z, Xu J, Zhang X, Tu Y, Lei J, et al. Bioactive sesquiterpenes from Inula helenium. Bioorg Chem. 2021; 114: 105066. doi: 10.1016/j.bioorg.2021.105066

9. Jung YS, Jeong YJ, Kim JH, Jeon CH, Lee SO. Elecampane (Inula helenium) Root Extract and Its Major Sesquiterpene Lactone, Alantolactone, Inhibit Adipogenesis of 3T3-L1 Preadipocytes. Molecules. 2022; 27(15): 4765. doi: 10.3390/molecules27154765

10. Jung YS, Lee HS, Cho HR, Kim KJ, Kim JH, Safe S, et al. Dual targeting of Nur77 and AMPKa by isoalantolactone inhibits adipogenesis in vitro and decreases body fat mass in vivo. Int J Obes (Lond). 2019; 43(5): 952-962. doi: 10.1038/s41366-018-0276-x

11. Tavares WR, Seca AML. Inula L. Secondary Metabolites against Oxidative Stress-Related Human Diseases. Antioxidants. 2019; 8(5): 122. doi: 10.3390/antiox8050122

12. Rubin GM, Yandell MD, Wortman JR, Gabor Miklos GL, Nelson CR, Hariharan IK, et al. Science. 2000; 287(5461): 2204-15. doi: 10.1126/science.287.5461.2204

13. Eriksson A, Raczkowska M, Navawongse R, Choudhury D, Stewart JC, Tang YL, et al. Neuromodulatory circuit effects on Drosophila feeding behaviour and metabolism. Sci Rep. 2017; 7(1): 8839. doi: 10.1038/s41598-017-08466-0

14. Lin S, Senapati B, Tsao CH. Neural basis of hunger-driven behaviour in Drosophila. Open Biol. 2019; 9(3): 180259. doi: 10.1098/rsob.180259

15. Erion R, King AN, Wu G, Hogenesch JB, Sehgal A. Neural clocks and Neuropeptide F/Y regulate circadian gene expression in a peripheral metabolic tissue. Elife. 2016; 5: e13552. doi: 10.7554/eLife.13552

16. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci. 2006; 361(1471): 1159-85. doi: 10.1098/rstb.2006.1855

17. Chen X, Yu Y, Zheng P, Jin T, He M, Zheng M, et al. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice. Psychoneuroendocrinology. 2020; 114: 104594. doi: 10.1016/j.psyneuen.2020.104594

18. Palasz A, Bandyszewska M, Rojczyk E, Wiaderkiewicz R. Effect of extended olanzapine administration on POMC and neuropeptide Y mRNA levels in the male rat amygdala and hippocampus. Pharmacol Rep. 2016; 68(2): 292-6. doi: 10.1016/j.pharep.2015.09.012

19. Varlamov O, Kievit P, Phu K, Reddy AP, Roberts CT Jr, Bethea CL. Preliminary Examination of Olanzapine and Diet Interactions on Metabolism in a Female Macaque. J Endocrinol Diabetes. 2014; 1(2): 9. doi: 10.15226/2374-6890/1/2/00112

20. Industrial technology of drugs. Vol. 2. NFAU MTK, Har'kov, 2002 (In Russ.).

21. Gargano JW, Martin I, Bhandari P, Grotewiel MS. Rapid iterative negative geotaxis (RING): a new method for assessing age-related locomotor decline in Drosophila. Exp Gerontol. 2005; 40(5): 386-95. doi: 10.1016/j.exger.2005.02.005

22. Madabattula ST, Strautman JC, Bysice AM, O'Sullivan JA, Androschuk A, Rosenfelt C, et al. Quantitative Analysis of Climbing Defects in a Drosophila Model of Neurodegenerative Disorders. J Vis Exp. 2015; (100): e52741. doi: 10.3791/52741

23. Eickelberg V, Lüersen K, Staats S, Rimbach G. Phenotyping of Drosophila Melanogaster - A Nutritional Perspective. Biomolecules. 2022; 12(2): 221. doi: 10.3390/biom12020221

24. Rajan A, Perrimon N. Drosophila cytokine un-paired 2 regulates physiological homeostasis by remotely controlling insulin secretion. Cell. 2012; 151(1): 123-37. doi: 10.1016/j.cell.2012.08.019. Erratum in: Cell. 2013 Feb 28; 152(5): 1197.